Part 5 - Why We Relapse: The Hidden Biological Memory of Addiction

Mohamad-Ali Salloum, PharmD • April 5, 2026

Share

  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
🧠

Relapse is not a failure — it's the brain remembering addiction on a biological level.

Relapse is one of the most challenging and misunderstood aspects of addiction. People often assume relapse is a failure of motivation or willpower — but neuroscience tells a very different story.

Modern research reveals that addiction leaves deep, long‑lasting biological marks on the brain. These changes are often epigenetic, meaning they alter gene expression without modifying the underlying DNA. These molecular “memories” of drug use can persist for months or years, making relapse a biological risk even long after detoxification.

This article explores the cutting‑edge science behind relapse:

  • how drug‑cue associations become hardwired,
  • how epigenetic enzymes reshape neural circuits,
  • why stress and environment reignite cravings, and
  • why relapse is a predictable biological process — not a moral failure.

1. Relapse Begins in the Brain’s Memory Systems

A 2025 ScienceDaily‑reported study found that relapse risk is driven by drug‑associated memory traces encoded in the brain’s reward and learning circuits. These memories link environmental cues — places, people, emotions — with past drug use. Importantly, they do not fade like ordinary memories. They become pathologically strong.

The study identified histone deacetylase 5 (HDAC5) as a key regulator of these powerful drug memories. HDAC5 suppresses expression of the gene Scn4b , which helps regulate neuronal excitability. When HDAC5 activity is altered, the neural circuits that encode drug‑cue memories become more excitable and more easily reactivated. This reactivation triggers craving and increases the odds of relapse.

🧩 In simple terms: Drug memories become too strong, and the brain becomes too eager to “remember” how rewarding the drug felt.

2. Epigenetics: The Biological ‘Scar’ Left by Addiction

Epigenetics refers to chemical modifications — like methylation and acetylation — that alter gene activity. These changes can last long after the drug is gone.

The 2025 findings highlight that addiction creates long‑term epigenetic marks in neurons associated with reward, reinforcement, and craving. HDAC5 and related enzymes modify chromatin, altering how easily certain genes are activated.

The result:

  • drug‑cue neural pathways become “primed”
  • cues reactivate drug‑seeking behavior
  • cravings can resurface unexpectedly, even years later
🧩 In simple terms: The brain becomes biologically trained to crave — and this training is written into gene expression patterns.

3. Relapse as a Three‑Stage Neurocircuitry Process

Relapse is not random — it is the final step in a three‑stage addiction cycle:

Binge/Intoxication
Dopamine floods the nucleus accumbens, creating strong reinforcement circuits.

Withdrawal / Negative Affect
The extended amygdala produces stress and dysphoria, driving the person to seek relief.

Preoccupation / Anticipation (Craving)
The prefrontal cortex becomes compromised, weakening decision‑making and self‑control.

This model explains how relapse occurs when cues activate sensitized circuits while cognitive control circuits remain weakened.

🧩 In simple terms:
The reward system says “I want it,”
the stress system says “I need it,”
and the decision‑making system loses the ability to say “no.”

4. Why Cues Can Trigger Relapse After Years of Sobriety

Environmental cues play a major role in relapse. A 2025 neuroscience chapter shows that drug‑associated cues can reactivate neural ensembles — clusters of neurons formed during drug use. When these circuits fire, cravings surge.

Examples of potent cues:

  • seeing a bar or former using location
  • encountering someone previously used with
  • hearing certain music
  • experiencing stress, disappointment, or anger

Once activated, these circuits can trigger intense cravings even after long abstinence.

🧩 In simple terms: Just like the smell of cookies makes you crave them, drug cues reignite urges — but far more intensely.

5. Stress and Negative Emotion: The Fuel for Relapse

Withdrawal and long‑term abstinence alter stress circuits, creating:

  • irritability
  • anxiety
  • emotional blunting
  • anhedonia (inability to feel pleasure)

These emotional states increase vulnerability to relapse. The brain seeks relief — and the drug provides a rapid but temporary escape.

Theories like allostasis explain this as the brain developing a new, unhealthy baseline where reward is reduced and stress elevated. Relapse briefly restores the imbalance.

🧩 In simple terms: Relapse often occurs because the brain feels “off‑balance” — the drug temporarily restores stability.

6. Why Relapse Is Biological — Not a Personal Failure

Modern neuroscience shows relapse is driven by:

  • long‑lasting epigenetic changes
  • hyper‑reactive drug cues
  • weakened decision‑making circuits
  • persistent stress states
  • maladaptive learning loops

These factors create a neurobiological environment where relapse becomes predictable — not a sign of weakness.

Understanding relapse as a biological process allows for:

  • better treatment strategies
  • more targeted interventions
  • reduced stigma
  • greater empathy for those affected

✅ Mini‑Exercise: Test Your Understanding

  1. Explain in your own words how epigenetic changes contribute to relapse.
  2. Name a common environmental cue that could trigger relapse. Why does it work?
  3. Which brain region becomes hypersensitive to drug cues?
  4. How do stress circuits influence relapse risk?
  5. Why is relapse considered a biological event rather than a failure of willpower?

Scroll up to review the sections and reflect on your answers.


References:

  1. Biological Psychiatry Study. HDAC5 limits expression of Scn4b and regulates drug memory formation and relapse. ScienceDaily. 2025. 1 
  2. Fang Y, Sun Y, Liu Y, et al. Neurobiological mechanisms and clinical treatment of addiction. Psychoradiology. 2022;2(4):180189. 2 
  3. Palombo P. Neurobiology of Substance Use Disorders. Springer; 2025. 3 





List of Services

    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button

    ABOUT THE AUTHOR

    Mohamad-Ali Salloum, PharmD

    Mohamad Ali Salloum LinkedIn Profile

    Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.

    Share

    Recent articles:

    By Mohamad-Ali Salloum, PharmD May 19, 2026
    Stuck in your head? Discover why overthinking feels productive, how it sabotages your performance, and simple ways to shift into real action.
    By Mohamad-Ali Salloum, PharmD May 17, 2026
    References: Wood W, Quinn JM, Kashy DA. Habits in everyday life: Thought, emotion, and action. J Pers Soc Psychol . 2002;83(6):1281–1297. Wood W, Neal DT. The habitual consumer. J Consum Psychol . 2009;19(4):579–592. Neal DT, Wood W, Labrecque JS, Lally P. How do habits guide behavior? Perceived and actual triggers of habits in daily life. J Exp Soc Psychol . 2012;48(2):492–498. Wood W, Mazar A, Neal DT. Habits and goals in human behavior: Separate but interacting systems. Perspect Psychol Sci . 2021;16(1):1–16. Graybiel AM. Habits, rituals, and the evaluative brain. Annu Rev Neurosci . 2008;31:359–387. Smith KS, Graybiel AM. Habit formation. Dialogues Clin Neurosci . 2016;18(1):33–43. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci . 2006;7(6):464–476. Graybiel AM. The basal ganglia and chunking of action repertoires. Neurobiol Learn Mem . 1998;70(1–2):119–136. Schultz W. Dopamine reward prediction error coding. Dialogues Clin Neurosci . 2016;18(1):23–32. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science . 1997;275(5306):1593–1599. Nasser HM, Calu DJ, Schoenbaum G, Sharpe MJ. The dopamine prediction error: Contributions to associative models of reward learning. Front Psychol . 2017;8:244. Kahnt T, Schoenbaum G. The curious case of dopaminergic prediction errors and learning associative information beyond value. Nat Rev Neurosci . 2025;26:169–178. Lally P, van Jaarsveld CHM, Potts HWW, Wardle J. How are habits formed: Modelling habit formation in the real world. Eur J Soc Psychol . 2010;40(6):998–1009. American Psychological Association. Harnessing the power of habits. Monitor Psychol . 2020;51(8):78–83.
    By Mohamad-Ali Salloum, PharmD May 15, 2026
    References: Baddeley A. Working memory: theories, models, and controversies. Annu Rev Psychol . 2012;63:1–29. Chai WJ, Abd Hamid AI, Malin Abdullah J. Working memory from the psychological and neurosciences perspectives: a review. Front Psychol . 2018;9:401. Rogers RD, Monsell S. Costs of a predictable switch between simple cognitive tasks. J Exp Psychol Gen . 1995;124(2):207–231. Rubinstein JS, Meyer DE, Evans JE. Executive control of cognitive processes in task switching. J Exp Psychol Hum Percept Perform . 2001;27(4):763–797. Garner KG, Dux PE. Knowledge generalization and the costs of multitasking. Nat Rev Neurosci . 2023;24:98–112. Zhou X, Lei X. Wandering minds with wandering brain networks. Neurosci Bull . 2018;34(6):1017–1028. Sorella S, Crescentini C, Matiz A, et al. Resting‑state default mode network variability predicts spontaneous mind‑wandering. Front Hum Neurosci . 2025;19:1515902. Sweller J. Cognitive load during problem solving: effects on learning. Cogn Sci . 1988;12(2):257–285. 
    By Mohamad-Ali Salloum, PharmD May 13, 2026
    Why do we procrastinate even when tasks matter most? Discover the emotional roots of procrastination and how to stop
    By Mohamad-Ali Salloum, PharmD May 11, 2026
    Confidence and self-esteem are often confused but are psychologically distinct. Learn how they differ, how each develops, and why understanding both matters for real growth.
    By Mohamad-Ali Salloum, PharmD May 9, 2026
    Confidence isn’t about eliminating fear—it’s about acting despite it. Discover how courage, discomfort, and psychological growth build real confidence over time.
    By Mohamad-Ali Salloum, PharmD May 7, 2026
    References: McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med . 2014;371(11):993–1004. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med . 2007;357:2109–2122. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med . 2008;358:1431–1443. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358:2545–2559. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med . 1991;324:781–788. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on cardiovascular and renal outcomes. N Engl J Med . 2020;383:1413–1424. Ioannidis JPA. Surrogate endpoints in clinical trials: are we being misled? BMJ . 2013;346:f314.
    By Mohamad-Ali Salloum, PharmD May 4, 2026
    References: Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci . 2015;16(7):403‑18. Frisaldi E, Shaibani A, Benedetti F, Pagnini F. Placebo and nocebo effects associated with pharmacological interventions: an umbrella review. BMJ Open . 2023;13:e077243. Colloca L, Finniss D. Nocebo effects, patient‑clinician communication, and therapeutic outcomes. JAMA . 2012;307(6):567‑8. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a blinded, randomized trial of statin, placebo, and no treatment. N Engl J Med . 2021;385(23):2180‑9. Penson PE, Mancini GBJ, Toth PP, et al. Introducing the “drucebo” effect in statin therapy. J Cachexia Sarcopenia Muscle . 2018;9(6):1023‑33. Barnes K, Faasse K, Geers AL, et al. Can positive framing reduce nocebo side effects? Front Pharmacol . 2019;10:167. Caliskan EB, Bingel U, Kunkel A. Translating knowledge on placebo and nocebo effects into clinical practice. Pain Rep . 2024;9(2):e1142. von Wernsdorff M, Loef M, Tuschen‑Caffier B, Schmidt S. Effects of open‑label placebos in clinical trials: a systematic review and meta‑analysis. Sci Rep . 2021;11:3855.
    By Mohamad-Ali Salloum, PharmD May 4, 2026
    References: Zaniletti I, Larson DR, Lewallen DG, Berry DJ, Maradit Kremers H. How to distinguish correlation from causation in orthopaedic research. J Arthroplasty. 2023;38(4):634–637. Rush J, Ajami M, Look KA, Margolis A. Statistics review part 10: causality and confounding. J Pharm Soc Wis. 2014;17(1):45–52. Koopmans E, Schiller C. Understanding causation in healthcare: an introduction to critical realism. Qual Health Res. 2022;32(8–9):1207–1214. Kahlert J, Gribsholt SB, Gammelager H, Dekkers OM, Luta G. Control of confounding in the analysis phase – an overview for clinicians. Clin Epidemiol. 2017;9:195–204. Shi AX, Zivich PN, Chu H. A comprehensive review and tutorial on confounding adjustment methods for estimating treatment effects using observational data. Appl Sci (Basel). 2024;14(9):3662. Gao Y, Xiang L, Yi H, Song J, Sun D, Xu B, et al. Confounder adjustment in observational studies investigating multiple risk factors: a methodological study. BMC Med. 2025;23:132. Ho FK, Brown J, Galwey NW. Regression adjustment for causal inference. BMJ Med. 2025;4:e000816. Correia LCL, Mascarenhas RF, Menezes FSC, Oliveira Junior JS, Vaccarino V, Ross JS, et al. Confounder selection in observational studies in high‑impact medical and epidemiological journals. JAMA Netw Open. 2025;8(7):e2524176.
    By Mohamad-Ali Salloum, PharmD May 1, 2026
    Explore the difference between Sensitivity and Specificity
    More Posts